Gevo: Q1 Earnings Insights

Gevo (NASDAQ:GEVO) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:01 PM. Here’s what investors…

Gevo (NASDAQ:GEVO) reported its Q1 earnings results on Wednesday, May 10, 2023 at 04:01 PM.

Here’s what investors need to know about the announcement.

Earnings

Gevo missed estimated earnings by 16.67%, reporting an EPS of $-0.07 versus an estimate of $-0.06.

Revenue was up $3.83 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.05 which was followed by a 5.59% increase in the share price the next day.

Here’s a look at Gevo’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.06 -0.07 -0.08 -0.07
EPS Actual -0.11 -0.19 -0.06 -0.08
Revenue Estimate 1.92M 1.22M 400K 110K
Revenue Actual 545K 309K 89K 232K

To track all earnings releases for Gevo visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Earnings Outlook For Royal Bank of Canada

Royal Bank of Canada (NYSE:RY) is set to give its latest quarterly earnings report on Wednesday, 2022-08-24. Here's what investors need to know before the announcement. Analysts estimate that Royal Bank of Canada will report an earnings per share (EPS) of $2.68.

RY

Read More

Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?

Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients un

MCRB